Comparative Pharmacology
Head-to-head clinical analysis: MERETEK UBT KIT W PRANACTIN versus PRE PEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MERETEK UBT KIT W PRANACTIN versus PRE PEN.
MERETEK UBT KIT (W/ PRANACTIN) vs PRE-PEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Meretek UBT Kit contains [13C]urea; Helicobacter pylori urease hydrolyzes [13C]urea to produce [13C]CO2, which is detected in breath to indicate active H. pylori infection.
Benzylpenicilloyl polylysine is a skin test reagent that elicits a wheal-and-flare response in penicillin-allergic individuals by binding to penicillin-specific IgE antibodies on mast cells, triggering histamine release.
75 mg oral pranactin (citric acid) dissolved in 200 mL water, administered once for urea breath test.
0.25 mL intradermal injection of a 1:100 dilution (0.25 mg/mL) for skin testing; if negative, proceed to 0.05 mL intradermal injection of 1:10 dilution (2.5 mg/mL).
None Documented
None Documented
Not applicable; 13C is a stable isotope that is rapidly converted to 13CO2; elimination half-life of CO2 from the body is approximately 5-10 minutes under normal respiratory conditions. Clinical context: 13CO2 appearance in breath peaks at 30 minutes post-dose.
Terminal elimination half-life: 0.5-1.0 hour in patients with normal renal function. Clinical context: Rapid elimination allows for short duration of action; half-life is prolonged in renal impairment.
Urea (13C) is rapidly hydrolyzed by H. pylori urease in the stomach to 13CO2, which is absorbed and exhaled via the lungs; >99% of the 13C dose is eliminated as exhaled 13CO2 within 24 hours. Pranactin (citric acid) is metabolized to CO2 and water; <2% renal elimination.
Primarily renal excretion (60-80% as unchanged drug and metabolites). Biliary/fecal elimination accounts for <10%.
Category C
Category C
Diagnostic Agent
Diagnostic Agent